Berberine
Berberine has been studied in 406 papers since 1985: 89 trials and 3 observational studies in people, 73 in animals, 26 in cells, 207 reviews; 52 in the past year. The newest paper, Oct 31, 2026: “Selected Dietary and Supplemental Phytochemicals in Adiposity-Based Chronic Disease: Molecular Mechanisms, Human Evidence, and Translational Gaps”.
Research on it is growing 58% faster than aging research as a whole: 11 papers in the latest year counted
5 new papers in 30 daysSee all 246 papers on berberine
At a glance
Berberine extends lifespan in worms and flies, with independent replication in flies, although other experiments show no clear lifespan effect. A human trial reports reduced colorectal adenoma recurrence after polypectomy; independent labs reproduce LDL and total cholesterol reductions, although a human result shows no clear total cholesterol effect. Some papers have company-affiliated authors.
424 findings in 164 papers from 2003 to 2026, 14 of them since April 2026
Independent labs found the same change in cells, worms or flies, mice and people. 80 independent labs in 16 countries; 43 trials, 1 about aging, 15 with no results posted.
“lower adenoma recurrence rate (34.7% vs. 52.1%)”
20 of its findings point the other way.
- 80 independent labs in 16 countries
- 20 findings against
- 43 trials, 1 about aging, 15 with no results posted
- Funders: National Natural Science Foundation of China and others
- 16 of 336 findings with company ties
- Human trial58
- Humans2
- Animals33
- Model organisms9
- Cells7
- In silico2
Studies in people
See all 38 studies of berberine in people38 studies gave berberine to people and measured what changed.
What did lifespan studies of berberine find?
DrugAgeDrugAge records 7 results from 3 papers: 5 in C. elegans, 1 in D. melanogaster and 1 in mice. Average lifespan is the mean or the median, as each paper reports it.
What did studies of berberine find?
210Studies of berberine measured 210 outcomes; the most studied are inflammation (18 studies), LDL cholesterol (13) and body weight (13).
Inflammation
downin reviews7downin humans4downin mice4no changein humans1+2
18 studies
Inflammation
downin reviews7downin humans4downin mice4no changein humans1+2
Berberine inhibits inflammation in additive BBR-treated group compared with baseline levels.
“The decrease of hsCRP in additive BBR‐treated group was significant (p < 0.05), whereas the decrease in hsCRP in the control group did not reach significance (p > 0.05; Figure b).”
Human trialin additive BBR-treated group compared with baseline levels3 months
Phytotherapy research : PTR
Berberine showed no clear effect on inflammation in humans.
“Blood inflammatory factors (CRP, IL-6, TNFα, COX-2) and erythrocyte sedimentation rate (ESR) were not significantly affected by treatment with berberine.”
Human trial12 weeks
Lipid-lowering effect of berberine in human subjects and rats
Phytomedicine : international journal of phytotherapy and phytopharmacology
Berberine decreases inflammation.
“in adipose tissue, it attenuates adipogenesis, lipid accumulation and inflammation.”
Reviewadipose tissue
Effects of Berberine on Insulin-Sensitive Tissues: Nutrient-Derived Modulator of Metabolic Disease
Cells
Berberine inhibits inflammation in diverse clinical populations.
“concurrent cardiometabolic and anti-inflammatory improvements”
Reviewin diverse clinical populations
Nutrients
Berberine decreases inflammation in ovariectomized mice.
“This modulation led to the suppression of intestinal inflammation, evidenced by decreased expression of IL-1β, IL-6, IL-8, and TNF-α”
Animalsin ovariectomized miceintestine100 mg/kg/day
Naunyn-Schmiedeberg's archives of pharmacology
Berberine decreases inflammation in rats (HFD/STZ-induced diabetic nephropathy).
“Furthermore, BHC-Lip or Vild treatments markedly reduced serum inflammatory cytokines”
AnimalsHFD/STZ-induced diabetic nephropathy
Tissue & cell
Berberine decreases inflammation in aged mice undergoing surgery and anaesthesia.
“BBR markedly suppressed glial cell activation and reduced levels of pro-inflammatory cytokines such as tumour necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β)”
Animalsin aged mice undergoing surgery and anaesthesia10 mg/kg daily2 weeks
Journal of cellular and molecular medicine
Berberine decreases inflammation.
“Berberine exerts potent antibacterial, anti-inflammatory, and therapeutic effects in cardiovascular, neurological, metabolic, and tumor-related conditions by modulating key intracellular signaling pathways”
Review
Multiple target and regulatory pathways of berberine
Phytomedicine : international journal of phytotherapy and phytopharmacology
Berberine decreases inflammation in atherosclerosis.
“BBR reduced inflammation linked to SASP in atherosclerosis through the RXRα/PPARγ/NEDD4 signaling pathway.”
Animalsin atherosclerosis
Berberine Inhibited SASP-Related Inflammation through RXRα/PPARγ/NEDD4 Pathway in Atherosclerosis
The American journal of Chinese medicine
Berberine decreases inflammation in zebrafish (atorvastatin-induced intracerebral hemorrhage).
“BBR was found to reduce brain inflammation and locomotion injury in ICH-zebrafish.”
Animalsatorvastatin-induced intracerebral hemorrhage10, 50, and 100 μM
Atorvastatin-induced intracerebral hemorrhage is inhibited by berberine in zebrafish
Journal of applied toxicology : JAT
All 18Fewer
LDL cholesterol
downin humans12downin Cricetinae1downin reviews1−42% to −25%
13 studies
LDL cholesterol
downin humans12downin Cricetinae1downin reviews1−42% to −25%
Berberine decreases LDL cholesterol in humans (versus placebo) (-7.72 mg/dL [95% CI, -13.13 to -1.93]).
“Berberine was associated with larger reductions in low-density lipoprotein cholesterol (-7.72 [95% CI, -13.13 to -1.93] mg/dL)”
Human trialversus placebo1 g/d6 monthsn = 337
JAMA network open
Berberine decreases LDL cholesterol in humans (compared with placebo).
“Berberine reduced total cholesterol, triglycerides and LDL cholesterol and increased HDL cholesterol after 3 months from randomization and compared with placebo.”
Human trialcompared with placebo500 mg twice a day3 months
Effects of berberine on lipid profile in subjects with low cardiovascular risk
Expert opinion on biological therapy
Berberine decreases LDL cholesterol in humans (compared with ezetimibe in hypercholesterolemic subjects) (-31.7% vs -25.4% with ezetimibe, P < 0.001).
“the nutraceutical pill resulted more effective than EZE in lowering LDL cholesterol (-31.7% vs -25.4%, P < 0.001)”
Human trialcompared with ezetimibe in hypercholesterolemic subjectsnutraceutical pill
Lipids in health and disease
Berberine decreases LDL cholesterol in monotherapy.
“The comparison of the two treatments in terms of percent lipid variations showed that BBR/P/RR was more effective than EZE in reducing TC, LDL-C and non-HDL-C levels, and showed a tendency to lower TG more than EZE.”
Human trialin monotherapysix months
Lipids in health and disease
Berberine decreases LDL cholesterol in humans (poorly controlled type 2 diabetes mellitus) (decreased significantly).
“Total cholesterol and low-density lipoprotein cholesterol were decreased significantly as well.”
Human trialpoorly controlled type 2 diabetes mellitus3 monthsn = 48
Efficacy of berberine in patients with type 2 diabetes mellitus
Metabolism: clinical and experimental
Berberine decreases LDL cholesterol in type 2 diabetic patients with dyslipidemia (from 3.23 +/- 0.81 to 2.55 +/- 0.77 mm/liter, P < 0.0001 vs placebo).
“low-density lipoprotein-cholesterol from 3.23 +/- 0.81 to 2.55 +/- 0.77 mm/liter, with all parameters differing from placebo significantly (P < 0.0001”
Human trialin type 2 diabetic patients with dyslipidemia1.0 g daily3 monthsn = 116
Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine
The Journal of clinical endocrinology and metabolism
Berberine decreases LDL cholesterol in humans (20% reduction).
“BERB and COMB significantly reduced TC (respectively by 16% and 20%), LDL (by 20% and 25%), ApoB (by 15% and 29%) and TG (by 22% and 26%)”
Human trial4 weeksn = 20
Arzneimittel-Forschung
Berberine decreases LDL cholesterol in humans (hypercholesterolemia) (-25%).
“Oral administration of BBR in 32 hypercholesterolemic patients for 3 months reduced serum cholesterol by 29%, triglycerides by 35% and LDL-cholesterol by 25%.”
Human trialhypercholesterolemiaoral3 monthsn = 32
Nature medicine
Berberine decreases LDL cholesterol in humans (versus control) (MD -14.98 mg/dL [95%CI: -20.67 to -9.28]).
“Berberine containing products significantly reduced TC (MD -17.42 mg/dL [95%CI: -22.91 to -11.93]), LDL (MD -14.98 mg/dL [95%CI: -20.67 to -9.28])”
Reviewversus controlberberine-containing products8-18 wkn = 4,838
Journal of dietary supplements
Berberine decreases LDL cholesterol in humans (-0.46 mmol/L (95% CI -0.62 to -0.30)).
“Berberine reduced LDL cholesterol (- 0.46 mmol/L, 95% CI - 0.62 to - 0.30, 14 studies, n = 1447)”
Review4 to 24 weeksn = 1,447
Drugs
All 15Fewer
Body weight
downin humans10upin mice1no changein mice1downin reviews1
13 studies
Body weight
downin humans10upin mice1no changein mice1downin reviews1
Berberine decreases body weight in humans.
“BBR significantly decreased (p < 0.05) body weight, blood pressure and Vis and Ap gene expression”
Human trial3 months
Nutrients
Berberine decreases body weight in humans (people living with HIV under virological suppression and metabolic syndrome).
“The berberine group showed a reduction in weight and body mass index, lower insulin resistance, and a reduction in TNF-alpha.”
Human trialpeople living with HIV under virological suppression and metabolic syndrome500 mg TID20 weeks
International journal of STD & AIDS
Berberine decreases body weight in humans (schizophrenia spectrum disorders with metabolic syndrome) (MD -1.08, 95% CI -1.76 to -0.40, P = 0.002, d = 0.59).
“Compared with the placebo group, the berberine group showed a significantly greater reduction in weight gain at 9 weeks (mean difference [MD], -0.75; 95% CI, -1.42 to -0.07 [P = 0.031, d = 0.41]) and 12 weeks (MD, -1.08; 95% CI, -1.76 to -0.40 [P = 0.002, d = 0.59]).”
Human trialschizophrenia spectrum disorders with metabolic syndrome600 mg/d12 weeksn = 113
Psychiatry and clinical neurosciences
Berberine decreases body weight in patients with schizophrenia on stable antipsychotic treatment (-1.10 kg vs +1.45 kg, P = 0.001).
“At the 8th week, the mean weight of patients in the berberine group (N = 27) lost 1.10 kg, while in the placebo group (N = 22) gained 1.45 kg.”
Human trialin patients with schizophrenia on stable antipsychotic treatment900 mg per day8-weekn = 49
Asian journal of psychiatry
Berberine decreases body weight in humans (mildly overweight patients with non-alcoholic fatty liver disease).
“reduced body weight, and improved insulin sensitivity in mildly overweight patients with non-alcoholic fatty liver disease”
Human trialmildly overweight patients with non-alcoholic fatty liver disease1 month
Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans
Cell death & disease
Berberine decreases body weight (-4.29(-5.04 –-3.54)kg vs -1.99(-2.76 –-1.23)kg).
“In comparison with LSI alone, BBR exhibited extra decreases in body weight [-4.29(-5.04 –-3.54)kg vs -1.99(-2.76 –-1.23)kg, p<0.001”
Human trial16-weeksn = 184
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
PloS one
Berberine decreases body weight in humans (plus LSI) (p<0.05).
“paralleled with better improvement in body weight, HOMA-IR, and serum lipid profiles (all p<0.05).”
Human trialplus LSI0.5g tid16 weeks
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
PloS one
Berberine decreases body weight in humans (obese) (average 5 lb/subject).
“The results demonstrate that berberine treatment produced a mild weight loss (average 5 lb/subject) in obese human subjects.”
Human trialobese500 mg orally three times a day12 weeks
Lipid-lowering effect of berberine in human subjects and rats
Phytomedicine : international journal of phytotherapy and phytopharmacology
Berberine decreases body weight in humans (−0.88 kg (95% CI −1.36 to −0.39)).
“−0.88 kg (−1.36 to −0.39) for berberine.”
Review
Nutrients
Berberine decreases body weight in humans (MD -0.88 kg, 95% CI -1.36 to -0.39).
“Berberine significantly reduced body weight (MD of -0.88 kg, 95% CI: -1.36 to -0.39, p = 0.0003)”
Review
The effect of berberine on obesity indices: a systematic review and meta-analysis
International journal of obesity (2005)
All 14Fewer
Total cholesterol
downin humans11downin hamsters1no changein humans1
13 studies
Total cholesterol
downin humans11downin hamsters1no changein humans1
Berberine decreases total cholesterol in humans (MAFLD) (p=0.0009).
“a significant divergence between the BBR and placebo groups was evident in the alteration of Δ total cholesterol (TC) p=0.0009, favoring the BBR group”
Human trialMAFLDoral1500 mg/day12 weeksn = 70
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
Berberine decreases total cholesterol in overweight subjects with impaired fasting blood glucose, versus placebo (β=-0.25 (95% CI -0.45; -0.04), p=0.05).
“total cholesterol [β=-0.25, 95% C.I. (-0.45; -0.04), p=0.05]”
Human trialin overweight subjects with impaired fasting blood glucose, versus placebophytosome (phospholipid complex)2 tablets/day, 550 mg/tablettwo monthsn = 49
European review for medical and pharmacological sciences
Berberine decreases total cholesterol in humans (schizophrenia spectrum disorders with metabolic syndrome) (MD -0.58, 95% CI -0.74 to -0.41, P < 0.001, d = 1.31).
“Patients who received berberine also showed statistically significant improvements in end point in body mass index (MD, -0.41; 95% CI, -0.65 to -0.17 [P = 0.001, d = 0.64]), total cholesterol (MD, -0.58; 95% CI, -0.74 to -0.41 [P < 0.001, d = 1.31]), low-density lipoprotein (MD, -0.52; 95% CI, -0.68 to -0.35 [P < 0.001, d = 1.19]), and glycated hemoglobin (MD, -0.09; 95% CI, -0.18 to 0 [P = 0.05, d = 0.37]).”
Human trialschizophrenia spectrum disorders with metabolic syndrome600 mg/d12 weeksn = 113
Psychiatry and clinical neurosciences
Berberine decreases total cholesterol in humans.
“After 12 weeks of intervention, men taking berberine had a larger reduction in total cholesterol and HDL-c than those taking placebo.”
Human trial12 weeksmalesn = 84
Nutrients
Berberine decreases total cholesterol in humans (-0.39 mmol/L, 95% CI -0.70 to -0.08).
“Men randomized to berberine had larger reductions in total cholesterol (-0.39 mmol/L, 95% confidence interval (CI) -0.70 to -0.08) and high-density lipoprotein cholesterol (-0.07 mmol/L, 95% CI -0.13 to -0.01) after 12 weeks.”
Human trial500 mg orally, twice a day12 weeksmalesn = 80
Nutrients
Berberine decreases total cholesterol in humans (adjunctive treatment) (all p<0.05).
“Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo.”
Human trialadjunctive treatment900mg/day8 weeksn = 49
Psychiatry research
Berberine decreases total cholesterol in humans (mixed dyslipidemia).
“BBR reduced TC levels.”
Human trialmixed dyslipidemiaoral500 mg t.i.d.90 daysn = 12
Journal of medicinal food
Berberine decreases total cholesterol in humans (mild hyperlipidemia).
“TG, TC, and LDL-C all decreased, and HDL-C increased in the treatment group (all P < 0.05).”
Human trialmild hyperlipidemia300 mg thrice per day3 successive months
Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
Berberine decreases total cholesterol in humans (new diagnosed type 2 diabetes combining nonalcoholic fatty liver disease).
“ALT, AST, TC, TG, LDL-L, hemorrheology (including the whole blood viscosity, whole blood viscosity, high cutting reduction of whole blood viscosity, plasma cutting reductive low viscosity, blood sedimentation, RBC deposited, fibrinogen) were significantly lower than before”
Human trialnew diagnosed type 2 diabetes combining nonalcoholic fatty liver disease12 weeks
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
Berberine showed no clear effect on total cholesterol in humans (compared to routine or statins) (SMD 0.43, 95% CI -0.39 to 1.24).
“There were no differences between berberine alone and routine or statins in improving total cholesterol (TC) (SMD, 0.43; 95% CI, -0.39 to 1.24; p = 0.30; I2 = 95%)”
Reviewcompared to routine or statins
Phytomedicine : international journal of phytotherapy and phytopharmacology
All 14Fewer
HOMA-IR
downin humans9
9 studies
HOMA-IR
downin humans9
Berberine decreases HOMA-IR in humans (berberine alone versus baseline).
“Notably, there was a significant reduction in FBG and HOMA-IR with the BBR group compared to the baseline.”
Human trialberberine alone versus baselineapproximately 1000 mg dailymales
Physiological reports
Berberine decreases HOMA-IR in humans (2.41 ± 0.14 vs 3.40 ± 0.28 units).
“HOMA-IR showed a similar significant reduction for the treatment group with mean values after 84 days at 2.41 ± 0.14 units compared to the control group mean values at 3.40 ± 0.28 (p<10− 5), as shown in Table.”
Human trial84 daysn = 34
BMC endocrine disorders
Berberine decreases HOMA-IR in humans (prediabetes) (3.61 ± 0.31 to 2.41 ± 0.14, p<10- 5).
“HOMA-IR from 3.61 ± 0.31 to 2.41 ± 0.14.”
Human trialprediabetesHIMABERB®500 mg three times daily12 weeksn = 34
BMC endocrine disorders
Berberine decreases HOMA-IR in humans (mild metabolic disorders induced by olanzapine).
“FPG, FPI, HOMA-IR, HbA1, TG, BMI, and WC were significantly lower in patients who received berberine compared to placebo after 12 weeks of treatment”
Human trialmild metabolic disorders induced by olanzapine12 weeks
The American journal of Chinese medicine
Berberine decreases HOMA-IR (-1.06(-1.51 –-0.61) vs -0.26(-0.72–0.20)).
“In comparison with LSI alone, BBR exhibited extra decreases in body weight [-4.29(-5.04 –-3.54)kg vs -1.99(-2.76 –-1.23)kg, p<0.001], BMI [-1.51(-1.79 –-1.25)kg/m2 vs -0.72(-0.99 –-0.44) kg/m2, p<0.001], waist circumference[-4.84(-5.70 –-3.97)cm vs -2.14(-3.03 –-1.26)cm, p<0.001], HFC [-17.4(-20.8 –-14.0)% vs -11.4(-14.8 –-7.9)%, p = 0.008), 2h postload glucose [-2.19(-2.87 –-1.51)mmol/L vs -1.05(-1.73 –-0.37)mmol/L, p = 0.020), area under the OGTT curve [-6.14(-7.72 –-4.55) vs -3.33(-4.93 –-1.73), p = 0.015], HOMA-IR [-1.06(-1.51 –-0.61) vs -0.26(-0.72–0.20), p = 0.014], serum cholesterol [-0.52(-0.71 –-0.33)mmol/L vs -0.12(-0.31–0.07)mmol/L, p = 0.004], APO-B [-0.12(-0.16 –-0.08)g/L vs -0.05(-0.09–0.01)g/L, p = 0.022] and triglycerides [-0.45(-0.68 –-0.23)mmol/L vs -0.02(-0.24–0.21)mmol/L, p = 0.007], showing clearly a significant benefit of BBR in metabolism”
Human trial16-weeksn = 184
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
PloS one
Berberine decreases HOMA-IR in humans (plus LSI) (p<0.05).
“better improvement in body weight, HOMA-IR, and serum lipid profiles (all p<0.05).”
Human trialplus LSI0.5g tid16 weeks
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
PloS one
Berberine decreases HOMA-IR in humans (compared with placebo in infertile women with PCOS undergoing IVF treatment).
“greater reductions in total testosterone, free androgen index, fasting glucose, fasting insulin and HOMA-IR, and increases in SHBG, were observed in the berberine and metformin groups”
Human trialcompared with placebo in infertile women with PCOS undergoing IVF treatmenttablets3 monthsfemalesn = 150
The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment
Clinical endocrinology
Berberine decreases HOMA-IR in humans (poorly controlled type 2 diabetes mellitus) (reduced by 44.7% (P<.001)).
“homeostasis model assessment of insulin resistance index were reduced by 28.1% and 44.7% (P<.001), respectively”
Human trialpoorly controlled type 2 diabetes mellitus3 monthsn = 48
Efficacy of berberine in patients with type 2 diabetes mellitus
Metabolism: clinical and experimental
Berberine decreases HOMA-IR in humans (non-alcoholic fatty liver disease) (SMD = -1.56, 95% CI [-2.54, -0.58]).
“HOMA-IR (SMD = - 1.56, 95% CI [- 2.54, - 0.58], P = 0.002)”
Reviewnon-alcoholic fatty liver disease
Journal of translational medicine
Berberine decreases HOMA-IR in humans (-0.85, 95% CI -1.16 to -0.53).
“HOMA-IR (-0.85, 95% CI -1.16 to -0.53,12 studies, n = 1065)”
Reviewn = 1,065
The Journal of nutrition
All 11Fewer
Cellular senescence
downin mice4downin cells2downin human cells1downin rat cells1+1
8 studies
Cellular senescence
downin mice4downin cells2downin human cells1downin rat cells1+1
Berberine inhibits cellular senescence in cells (irradiated intestinal epithelial cells).
“inhibits radiation-induced cellular senescence and SASP in vitro”
Cellsirradiated intestinal epithelial cellsintestinal epithelial cells
Berberine alleviates radiation-induced intestinal injury by inhibiting cellular senescence
Radiation oncology (London, England)
Berberine decreases cellular senescence in mice (radiation-induced intestinal injury).
“BBR can alleviate radiation-induced DNA damage and senescence in mouse intestines”
Animalsradiation-induced intestinal injuryintestine
Berberine alleviates radiation-induced intestinal injury by inhibiting cellular senescence
Radiation oncology (London, England)
Berberine decreases cellular senescence in doxorubicin-induced senescent cells and natural aging mice.
“a potential candidate for attenuating hepatic senescence”
Animalsin doxorubicin-induced senescent cells and natural aging miceliver
Phytomedicine : international journal of phytotherapy and phytopharmacology
Berberine decreases cellular senescence in mice.
“BBR alleviates the aging of adipose tissue and adipose derived stem cells (ADSCs), thereby decreasing the secretion of senescence-associated secretory phenotype (SASP).”
Animalsadipose tissue
Translational oncology
Berberine protects against cellular senescence in rat cells (doxorubicin-induced senescence in H9c2 cells).
“BBR protected H9c2 cells against DOX-induced senescence.”
Cellsdoxorubicin-induced senescence in H9c2 cells
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Berberine decreases cellular senescence in mice (D-galactose-induced senescence).
“BBR down-regulated the expression of REDD1 to decrease intracellular ROS content, attenuating DG-induced senescence in vitro and in vivo.”
AnimalsD-galactose-induced senescenceretinal pigment epithelium
Phytomedicine : international journal of phytotherapy and phytopharmacology
Berberine decreases cellular senescence in human cells (cigarette smoke-induced).
“in 16HBE cells, berberine-LCNs inhibited the cigarette smoke-induced senescence as revealed by X-gal staining, gene expression of CDKN1A (p21)”
Cellscigarette smoke-induced16HBE
Antioxidants (Basel, Switzerland)
Berberine decreases cellular senescence.
“and attenuate premature cellular senescence”
Review
Aging and disease
Berberine decreases cellular senescence in cells (mitoxantrone-induced premature senescence).
“All these markers of senescence were distinctly diminished, in a concentration-dependent manner, by Berberine.”
Cellsmitoxantrone-induced premature senescence
Berberine suppresses gero-conversion from cell cycle arrest to senescence
Aging
AMPK signaling
upin reviews7upin humans1
8 studies
AMPK signaling
upin reviews7upin humans1
Berberine activates AMPK signaling.
“Berberine activates AMP-activated protein kinase (AMPK) via mild mitochondrial complex I inhibition”
Review
Fitoterapia
Berberine activates AMPK signaling in humans.
“Key nutraceuticals-phytosterols, omega-3 fatty acids, and berberine-demonstrate clinically meaningful effects through micellar competition, inflammation-resolving lipid mediators, and AMPK activation, respectively.”
Review
Biomedicines
Berberine activates AMPK signaling.
“exemplified by berberine via AMPK, curcumin via NF-κB, and resveratrol via SIRT1”
Review
Ageing research reviews
Berberine activates AMPK signaling.
“BBR, by contrast, primarily activates AMPK (AMP-activated protein kinase)”
Review
International journal of molecular sciences
Berberine activates AMPK signaling.
“berberine induces glucose metabolism by activating AMPK signaling”
Review
Addressing the preventive and therapeutic perspective of berberine against diabetes
Heliyon
Berberine activates AMPK signaling.
“activating the AMPK pathway”
Review
Berberine and Its Study as an Antidiabetic Compound
Biology
Berberine activates AMPK signaling.
“The activity of AMPK can be stimulated with the phytochemical berberine.”
Review
Nutraceutical and Dietary Strategies for Up-Regulating Macroautophagy
International journal of molecular sciences
Berberine activates AMPK signaling.
“via anti-oxidation and AMPK cellular kinase activation”
Review
Aging and disease
HbA1c
downin humans7
7 studies
HbA1c
downin humans7
Berberine decreases HbA1c in humans (−0.99 [−1.16, −0.83]% vs −0.59 [−0.75, −0.44]%).
“Thus, BBR and BBR with probiotics were both superior to the Plac in lowering HbA1c, but Prob was not.”
Human trial12 weeksn = 409
Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)
Nature communications
Berberine decreases HbA1c in humans (newly diagnosed T2D) (least-squares mean [95% CI], -0.99[-1.16, -0.83]% vs -0.59[-0.75, -0.44]%).
“BBR-alone group (-0.99[-1.16, -0.83]%) were significantly greater than that in the placebo and probiotics-alone groups (-0.59[-0.75, -0.44]%, -0.53[-0.68, -0.37]%, P < 0.001).”
Human trialnewly diagnosed T2D12-weekn = 409
Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)
Nature communications
Berberine decreases HbA1c in humans (newly diagnosed type 2 diabetes mellitus) (from 9.5%+/-0.5% to 7.5%+/-0.4%, P<.01).
“Significant decreases in hemoglobin A1c (from 9.5%+/-0.5% to 7.5%+/-0.4%, P<.01)”
Human trialnewly diagnosed type 2 diabetes mellitus0.5 g 3 times a day3 monthsn = 36
Efficacy of berberine in patients with type 2 diabetes mellitus
Metabolism: clinical and experimental
Berberine decreases HbA1c in type 2 diabetic patients with dyslipidemia (HbA1c from 7.5 +/- 1.0% to 6.6 +/- 0.7%, P < 0.0001 vs placebo).
“fasting and postload plasma glucose decreased from 7.0 +/- 0.8 to 5.6 +/- 0.9 and from 12.0 +/- 2.7 to 8.9 +/- 2.8 mm/liter, HbA1c from 7.5 +/- 1.0% to 6.6 +/- 0.7%”
Human trialin type 2 diabetic patients with dyslipidemia1.0 g daily3 monthsn = 116
Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine
The Journal of clinical endocrinology and metabolism
Berberine decreases HbA1c in metabolic disorders (ESWMD: -0.57; 95% CI: -0.68 to -0.46).
“reducing fasting blood glucose (FBG) (ESWMD: -0.77; 95% CI: -0.90 to -0.63, and ESSMD: -0.65; 95% CI: -0.83 to -0.47), hemoglobin A1C (HbA1C) (ESWMD: -0.57; 95% CI: -0.68 to -0.46)”
Reviewin metabolic disorders
Clinical therapeutics
Berberine decreases HbA1c in humans (-4.48 mmol/mol, 95% CI -6.53 to -2.44).
“HbA1c (-4.48 mmol/mol, 95% CI -6.53 to -2.44, 7 studies, n = 756)”
Reviewn = 756
The Journal of nutrition
Berberine decreases HbA1c in humans (applied alone or with standard diabetic therapies versus the control group) (MD = -0.73, 95% CI (-0.97, -0.51)).
“Analysis of berberine applied alone or with standard diabetic therapies versus the control group revealed significant reductions in HbA1c (MD = -0.73; 95% CI (-0.97, -0.51))”
Reviewapplied alone or with standard diabetic therapies versus the control group
Oxidative medicine and cellular longevity
Berberine decreases HbA1c in humans (type 2 diabetes mellitus) (WMD = -0.54 mmol/L, 95% CI: -0.93 to -0.15).
“Berberine treatment was associated with a better reduction on FPG (WMD = -0.54 mmol/L, 95% CI: -0.77 to -0.30), PPG (WMD = -0.94 mmol/L, 95% CI: -1.27 to -0.61), and HbA1c (WMD = -0.54 mmol/L, 95% CI: -0.93 to -0.15) than control groups”
Reviewtype 2 diabetes mellitus
Endocrine journal
Lifespan
upin worms3upin flies2upin mice1upin reviews1+27% mean lifespan
7 studies
Lifespan
upin worms3upin flies2upin mice1upin reviews1+27% mean lifespan
Berberine extends lifespan.
“to slow aging, and to extend lifespans and health spans of animals”
Review
Berberine induces pleiotropic beneficial effects via hormesis
Pharmacological research
Berberine extends lifespan in worms (+27% mean lifespan).
“berberine extended the mean lifespan of wild-type worms by 27%”
Model organisms
Berberine Extends Lifespan in C. elegans Through Multi-Target Synergistic Antioxidant Effects
Antioxidants (Basel, Switzerland)
Berberine extends lifespan in worms.
“five compounds (all-trans retinoic acid, berberine, fisetin, propranolol, and ritonavir) extended lifespan in Caenorhabditis elegans.”
Model organisms
eLifePreprint
Berberine extends lifespan in worms.
“We find that 10 μM berberine significantly extends healthy lifespan in wild type C. elegans.”
Model organisms10 μM
Archives of gerontology and geriatrics
Berberine extends lifespan in mice (chemotherapy-treated) (~52%).
“BBR extended the lifespan of chemotherapy-treated mice and naturally aged mice by ~52% and ~16.49%, respectively.”
Animalschemotherapy-treated
Aging cell
Berberine extends lifespan in flies.
“berberine has recently been reported to expand life span in Drosophila melanogaster”
Review
Aging and disease
Berberine extends lifespan in flies (wild-type flies).
“The results of our study showed that Berberine extended mean, median and maximum life span of female flies.”
Model organismswild-type fliesfemales
Berberine Prolongs Life Span and Stimulates Locomotor Activity of Drosophila melanogaster
American journal of plant sciences
C-reactive protein
downin humans6
6 studies
C-reactive protein
downin humans6
Berberine decreases C-reactive protein in humans (versus placebo) (-0.072 mg/dL [95% CI, -0.140 to -0.004]).
“high-sensitivity C-reactive protein (hs-CRP) (-0.072 [95% CI, -0.140 to -0.004] mg/dL) vs placebo”
Human trialversus placebo1 g/d6 monthsn = 337
JAMA network open
Berberine decreases C-reactive protein in humans (−0.072 [95% CI, −0.140 to −0.004] mg/dL).
“berberine was associated with larger reductions in LDL-C (−7.72 [95% CI, −13.13 to −1.93] mg/dL; P =.008), apoB (−3.42 [95% CI, −6.33 to −0.51] mg/dL; P =.02; to convert to g/L, multiply by 0.01) and hs-CRP (−0.072 [95% CI, −0.140 to −0.004] mg/dL; P =.04) compared with placebo”
Human trial6 monthsn = 337
JAMA network open
Berberine decreases C-reactive protein in metabolic disorders (ESWMD: -0.62; 95% CI: -0.74 to -0.50).
“C-reactive protein (CRP) (ESWMD: -0.62; 95% CI: -0.74 to -0.50, and ESSMD: -1.70; 95% CI: -2.21 to -1.19)”
Reviewin metabolic disorders
Clinical therapeutics
Berberine decreases C-reactive protein in adults (-1.33 mg/L).
“CRP levels (-1.33 mg/L)”
Reviewin adultsn = 1,600
Phytotherapy research : PTR
Berberine decreases C-reactive protein in patients with metabolic syndrome and related disorders (SMD = -1.54, 95% CI -1.86, -1.22, p < 0.05).
“Pooled estimates showed that the use of berberine could significantly reduce the concentration level of C-reactive protein (CRP) [standardized mean difference (SMD) = - 1.54, 95% confidence intervals (CI) - 1.86, - 1.22, p < 0.05]”
Reviewin patients with metabolic syndrome and related disordersn = 4,616
Inflammopharmacology
Berberine decreases C-reactive protein in humans (WMD = -0.42 mg/L, 95% CI -0.82, -0.03).
“C-reactive protein (CRP) concentrations (WMD = -0.42 mg/L, 95% CI -0.82, -0.03, P = 0.034)”
Review
Clinical nutrition ESPEN
Berberine decreases C-reactive protein in humans (MD -0.64 mg/L, 95% CI -0.67 to -0.61, P < 0.001).
“serum levels of CRP were decreased after BER supplementation (MD:-0.64 mg/L, 95% CI(-0.67 to -0.61) P < 0.001)”
Review
Complementary therapies in medicine
Triglyceride
downin humans6
6 studies
Triglyceride
downin humans6
Berberine decreases triglyceride in humans (newly diagnosed type 2 diabetes mellitus) (from 1.13+/-0.13 to 0.89+/-0.03 mmol/L, P<.05).
“plasma triglycerides (from 1.13+/-0.13 to 0.89+/-0.03 mmol/L, P<.05) were observed in the berberine group”
Human trialnewly diagnosed type 2 diabetes mellitus0.5 g 3 times a day3 monthsn = 36
Efficacy of berberine in patients with type 2 diabetes mellitus
Metabolism: clinical and experimental
Berberine decreases triglyceride in humans (non-alcoholic fatty liver disease) (SMD = -0.59, 95% CI [-0.86, -0.31]).
“TG (SMD = - 0.59, 95% CI [- 0.86, - 0.31], P < 0.0001)”
Reviewnon-alcoholic fatty liver disease
Journal of translational medicine
Berberine decreases triglyceride in humans (-0.34 mmol/L (95% CI -0.46 to -0.23)).
“triglycerides (- 0.34 mmol/L, 95% CI - 0.46 to - 0.23, 18 studies, n = 1661)”
Review4 to 24 weeksn = 1,661
Drugs
Berberine decreases triglyceride in humans (applied alone or with standard diabetic therapies versus the control group) (MD = -0.5, 95% CI (-0.61, -0.39)).
“Lipid metabolisms were also ameliorated via the reduction of TG (MD = -0.5, 95% CI (-0.61, -0.39))”
Reviewapplied alone or with standard diabetic therapies versus the control group
Oxidative medicine and cellular longevity
Berberine decreases triglyceride in humans (compared with simvastatin) (MD=-0.37, 95% CI: -0.66, -0.07, P=0.02).
“Compared with the simvastatin group, berberine was effective only in reducing the level of triglyceride ( MD=-0.37 , 95% CI: - 0.66, - 0.07, P=0.02 ).”
Reviewcompared with simvastatin
The American journal of Chinese medicine
Berberine decreases triglyceride in humans (hyperlipidemia and other dyslipidemias) (reductions ranging from approximately 25 to 55 mg/dL).
“majority of evaluated articles consistently suggest that berberine has a beneficial effect on low-density lipoprotein (reductions ranging from approximately 20 to 50 mg/dL) and triglycerides (reductions ranging from approximately 25 to 55 mg/dL).”
Reviewhyperlipidemia and other dyslipidemias
Journal of evidence-based complementary & alternative medicine
HDL cholesterol
upin humans6+6.6% increase
6 studies
HDL cholesterol
upin humans6+6.6% increase
Berberine increases HDL cholesterol in humans (compared with placebo).
“Berberine reduced total cholesterol, triglycerides and LDL cholesterol and increased HDL cholesterol after 3 months from randomization and compared with placebo.”
Human trialcompared with placebo500 mg twice a day3 months
Effects of berberine on lipid profile in subjects with low cardiovascular risk
Expert opinion on biological therapy
Berberine increases HDL cholesterol in humans (new diagnosed type 2 diabetes combining nonalcoholic fatty liver disease).
“however, HDL-L significantly increased (P<0.05).”
Human trialnew diagnosed type 2 diabetes combining nonalcoholic fatty liver disease12 weeks
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
Berberine increases HDL cholesterol in humans (6.6% increase).
“increased HDL (by 6.6% and 5.1%)”
Human trial4 weeksn = 20
Arzneimittel-Forschung
Berberine increases HDL cholesterol in women; sex-specific effect (0.11 mmol/L (95% CI 0.09 to 0.13)).
“the effect on HDL cholesterol was different in women (0.11 mmol/L, 95% CI 0.09 to 0.13)”
Reviewin women; sex-specific effect4 to 24 weeksfemales
Drugs
Berberine increases HDL cholesterol in humans (alone or along with lipid lowing drugs in patients with dyslipidemia).
“use berberine alone or along with lipid lowing drugs could reduce TC, TG, LDL-C levels and increased HDL-C levels with statistically significant difference”
Reviewalone or along with lipid lowing drugs in patients with dyslipidemia
Systematic review and Meta-analysis on efficacy and safety of berberine for dyslipidemia
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
Berberine increases HDL cholesterol in humans (when used alone in patients with dyslipidaemias) (MD = 0.08 mmol/l 95% CI [0.03, 0.12], p = 0.001).
“Berberine also increased the level of high-density lipoprotein cholesterol (HDL-C) when used alone (MD = 0.08 mmol/l 95% CI [0.03, 0.12], p = 0.001).”
Reviewwhen used alone in patients with dyslipidaemias
Phytomedicine : international journal of phytotherapy and phytopharmacology
Low-density lipoprotein cholesterol
downin humans5
5 studies
Low-density lipoprotein cholesterol
downin humans5
Berberine decreases low-density lipoprotein cholesterol in humans (−7.72 [95% CI, −13.13 to −1.93] mg/dL).
“berberine was associated with larger reductions in LDL-C (−7.72 [95% CI, −13.13 to −1.93] mg/dL; P =.008”
Human trial6 monthsn = 337
JAMA network open
Berberine decreases low-density lipoprotein cholesterol in humans (adjunctive treatment) (all p<0.05).
“Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo.”
Human trialadjunctive treatment900mg/day8 weeksn = 49
Psychiatry research
Berberine decreases low-density lipoprotein cholesterol in women with PCOS and IR receiving compound cyproterone acetate (P<0.05).
“total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDLC; P<0.05) as well as increase in high-density lipoprotein cholesterol (HDLC)”
Human trialin women with PCOS and IR receiving compound cyproterone acetate3 monthsfemales
European journal of endocrinology
Berberine decreases low-density lipoprotein cholesterol in humans (compared with placebo) (P<0.05).
“berberine could significantly reduce the total cholesterol and low-density lipoprotein levels and elevate the high density lipoprotein level”
Reviewcompared with placebo
The American journal of Chinese medicine
Berberine decreases low-density lipoprotein cholesterol in humans (adults) (MD -0.65 mmol/L, 95% CI -0.76 to -0.54).
“low-density lipoprotein cholesterol (mean difference - 0.65 mmol/L; 95 % confidence interval - 0.76 to - 0.54) levels”
Reviewadultsn = 874
Planta medica
Fasting blood glucose
downin humans3no changein humans1
4 studies
Fasting blood glucose
downin humans3no changein humans1
Berberine decreases fasting blood glucose in humans (5.33 ± 0.28 vs 6.16 ± 0.44 mmol/L).
“FPG after 84 days was significantly lower in the treatment group than in the control group, with a mean FPG of 5.33 ± 0.28 mmol/L for the treatment group and 6.16 ± 0.44 mmol/L for the control group (p<10− 5).”
Human trial84 daysn = 34
BMC endocrine disorders
Berberine decreases fasting blood glucose in humans (prediabetes) (p<10- 5).
“Significant decreases in all markers of glycemic control were observed in the treatment group at intermediate time points and the endpoint of the study compared to baseline levels and to the control group.”
Human trialprediabetesHIMABERB®500 mg three times daily12 weeksn = 34
BMC endocrine disorders
Berberine showed no clear effect on fasting blood glucose.
“These findings led us to conclude that BBR significantly increases insulin secretion under hyperglycemic conditions but does not affect basal glucose levels in humans.”
Human trial160 minmalesn = 15
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
Nature communications
Berberine decreases fasting blood glucose in humans (type 2 diabetes mellitus).
“BBR significantly lowered fasting blood glucose (FBG), hemoglobin A(1c), triglyceride, and insulin levels in patients with type 2 diabetes mellitus (T2DM).”
Human trialtype 2 diabetes mellitus
Metabolism: clinical and experimental
Berberine decreases fasting blood glucose in metabolic disorders (ESWMD: -0.77; 95% CI: -0.90 to -0.63).
“BBR supplementation was effective in reducing fasting blood glucose (FBG)”
Reviewin metabolic disorders
Clinical therapeutics
Blood pressure
no changein humans2downin humans2downin reviews1
4 studies
Blood pressure
no changein humans2downin humans2downin reviews1
Berberine showed no clear effect on blood pressure in humans.
“Changes in triglycerides, thromboxane A2, blood pressure, body mass index and waist-hip ratio after the intervention did not differ between the berberine and placebo groups.”
Human trial500 mg orally, twice a day12 weeksmalesn = 80
Nutrients
Berberine decreases blood pressure.
“lower blood pressure”
Review
Integrative medicine (Encinitas, Calif.)
Berberine decreases blood pressure in humans (compared to placebo) (-11.80 [-18.73, -4.87] mmHg systolic).
“A proprietary nutraceutical containing berberine as one of its ingredients was in one study significantly effective at reducing blood pressure compared to placebo”
Reviewcompared to placeboproprietary nutraceutical containing berberine as one of its ingredients
Berberine for the treatment of hypertension: A systematic review
Complementary therapies in clinical practice
Berberine showed no clear effect on blood pressure in humans (compared to amlodipine alone).
“Berberine plus amlodipine was not significantly better than amlodipine alone at reducing systolic and diastolic blood pressure.”
Reviewcompared to amlodipine alone
Berberine for the treatment of hypertension: A systematic review
Complementary therapies in clinical practice
Berberine decreases blood pressure in humans with lifestyle intervention or combined with oral hypotensor.
“berberine with lifestyle intervention tended to lower the level of blood pressure more than the lifestyle intervention alone or placebo did”
Reviewwith lifestyle intervention or combined with oral hypotensor
Journal of ethnopharmacology
All 210Fewer
What is berberine linked with?
15Studies link berberine with 15 measures, among them colorectal adenoma recurrence, body mass index and microbiome composition.
Colorectal adenoma recurrence
downin humans2RR 0.77
2 studies
Colorectal adenoma recurrence
downin humans2RR 0.77
Berberine lowers the risk of colorectal adenoma recurrence in humans after complete polypectomy of colorectal adenomas (RR 0.77 (95% CI 0.66-0.91), 36% vs 47%).
“155 (36%) participants in the berberine group and 216 (47%) in the placebo group were found to have recurrent adenoma during follow-up (unadjusted relative risk ratio for recurrence 0·77, 95% CI 0·66-0·91; p=0·001).”
Human trialafter complete polypectomy of colorectal adenomas0.3 g twice dailyup to 2 years
The lancet. Gastroenterology & hepatology
Berberine lowers the risk of colorectal adenoma recurrence in humans.
“Clinical trials indicate that BBR reduces the recurrence of colorectal adenomas”
Review
Metabolism open
Body mass index
downin humans1
1 study
Body mass index
downin humans1
Berberine is associated with body mass index in humans (PCOS; within-group change).
“In the berberine group, significant reductions were observed in BMI, fasting insulin, HOMA-IR, total cholesterol, triglycerides, and androstenedione.”
HumansPCOS; within-group change6 monthsfemalesn = 28
Journal of clinical medicine
Microbiome composition
mixedin humans1
1 study
Microbiome composition
mixedin humans1
Berberine is associated with microbiome composition in diverse clinical populations.
“Six of seven studies reported significant compositional shifts; the most extensively characterised changes-observed predominantly in T2DM populations-included enrichment of γ-Proteobacteria and depletion of butyrate-producing taxa”
Reviewin diverse clinical populations
Nutrients
Visfatin binding
mixedin silico1
1 study
Visfatin binding
mixedin silico1
Berberine is associated with visfatin binding in silico (molecular docking) (Binding free energy of -8.5 kcal/mol).
“Berberine had a binding free energy of -8.5 kcal/mol.”
In silicomolecular docking
Research SquarePreprint
Cardiometabolic outcomes
mixedin reviews1
1 study
Cardiometabolic outcomes
mixedin reviews1
Berberine is associated with cardiometabolic outcomes.
“Positive study-level signals are summarized in the cardiometabolic outcome class, null signals in the contextual adjacent evidence, cardiometabolic, immune and inflammation outcome classes, and negative signals in the contextual adjacent evidence outcome class.”
Review
Hypothesis-Generating Brief: Berberine hydrochloride — full paper
Preprint
insulin and IGF signaling
mixedin zebrafish1
1 study
insulin and IGF signaling
mixedin zebrafish1
Berberine is associated with insulin and IGF signaling in zebrafish during tail fin fold regeneration after transection.
“Berberine induced accelerated regeneration is associated with the involvement of Insulin, IGF, stress response, jak-stat, cytokine, and cellular reprogramming signaling pathways”
Animalsduring tail fin fold regeneration after transectiontail fin0.01%4 hours post transection
Transcriptome analysis of Berberine induced accelerated tail fin regeneration in Zebrafish larvae
Gene expression patterns : GEP
JAK–STAT signaling
mixedin zebrafish1
1 study
JAK–STAT signaling
mixedin zebrafish1
Berberine is associated with JAK–STAT signaling in zebrafish during tail fin fold regeneration after transection.
“Berberine induced accelerated regeneration is associated with the involvement of Insulin, IGF, stress response, jak-stat, cytokine, and cellular reprogramming signaling pathways”
Animalsduring tail fin fold regeneration after transectiontail fin0.01%4 hours post transection
Transcriptome analysis of Berberine induced accelerated tail fin regeneration in Zebrafish larvae
Gene expression patterns : GEP
Neurodegenerative disease
downin worms1
1 study
Neurodegenerative disease
downin worms1
Berberine lowers the risk of neurodegenerative disease in worms.
“berberine also delays neurodegenerative diseases such as Alzheimer's and polyglutamine diseases in a PMK-1/SKN-1dependent manner.”
Model organisms
Archives of gerontology and geriatrics
Bioavailability
downin reviews1
1 study
Bioavailability
downin reviews1
Berberine is associated with bioavailability (< 1%).
“factors such as poor solubility, low permeability, P-glycoprotein (P-gp) efflux, and hepatic-intestinal metabolism result in BBR having a low bioavailability (< 1%)”
Review
Research progress on pharmacological effects and bioavailability of berberine
Naunyn-Schmiedeberg's archives of pharmacology
Adverse events
upin humans1RR 2.91
1 study
Adverse events
upin humans1RR 2.91
Berberine raises the risk of adverse events in humans (versus placebo) (RR 2.91, 95% CI 1.24 to 6.85, p=0.01).
“BBR had more adverse events than placebo (RR 2.91, 95% CI 1.24 to 6.85, p=0.01).”
Reviewversus placebo
Journal of ethnopharmacology
Severe ovarian hyperstimulation syndrome
downin humans1
1 study
Severe ovarian hyperstimulation syndrome
downin humans1
Berberine lowers the risk of severe ovarian hyperstimulation syndrome in infertile women with PCOS undergoing IVF treatment.
“reduced the incidence of severe ovarian hyperstimulation syndrome”
Human trialin infertile women with PCOS undergoing IVF treatmenttablets3 monthsfemalesn = 150
The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment
Clinical endocrinology
All 15Fewer
Has berberine been tested in people?
1 of 43 about agingYes: 89 trials and 3 observational studies in people have been published, and 43 trials are registered.
About aging
Every condition in trials
Phase 4Active, not recruiting4 trials
Phase 4Recruiting4 trials
Phase 4Completed3 trials
Phase 4Completed3 trials
Phase 4Completed3 trials
Metabolic dysfunction-associated steatotic liver disease
Phase 4Completed3 trials
All 40Fewer
Stopped
NCT01697735TerminatedDyslipidemias
Because of lack of participants and funds
Trial sponsors
10 trialsPhase 45,070 people
Xijing Hospital of Digestive Diseases
10 trialsPhase 45,070 people
China National Center for Cardiovascular Diseases
2 trialsPhase 42,361 people
Nanjing First Hospital, Nanjing Medical University
2 trialsPhase 4920 people
2 trialsPhase 4920 people
Peking Union Medical College Hospital
2 trialsPhase 488 people
2 trialsPhase 464 people
Second Xiangya Hospital of Central South University
1 trialPhase 4240 people
How this record changed
Summary rewritten as its findings changed.
As it read before
Berberine extends fly lifespan across independent labs, but fly and worm tests also show no clear lifespan effect; human trials report replicated LDL reductions. One registered trial concerns aging; 15 trials across all uses ended over a year ago without posted results or linked papers. The National Natural Science Foundation of China funds 87 findings; 16 of 335 findings have company-affiliated authors.
Summary rewritten as its findings changed.
As it read before
Berberine extends worm lifespan; a mouse study reports improved healthspan, and a human trial reports fewer colorectal adenoma recurrences. Independent labs report lower human cholesterol and HOMA-IR, but cholesterol results disagree. No registered trials concern aging; across uses, 21 ended over a year ago without posted results or citing papers, and some authors work at companies.
Summary rewritten as its findings changed.
As it read before
In male rats exposed to sevoflurane, one study shows berberine reduces brain apoptosis and elevates brain BDNF. Reviews report that it extends lifespan, elicits biphasic hormetic responses, activates AMPK signaling, and inhibits both mTOR and NF-κB signaling.
Summary written from the findings.